AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$CYTK

Blum Robert I sold $527K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $70.24 ($0.53M total) on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Aug 31, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The sale represents a routine liquidity event with minimal market impact.

02

Market read

Limited relevance; primarily of interest to existing shareholders and short-term traders.

03

What to watch

Potential upcoming clinical trial results not reflected in this filing.

Relevance 4/10Novelty 4/10Timing: 2026-08-31 filing

Background

Form 4 disclosures provide first public notice of insider transactions.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

President & CEO Robert Blum sold 7,500 shares for $526,800 via a 10b5-1 plan.

Expected impact

Potential short-term dip of 0.5-1% as market digests insider sell.

Evidence & confidence

Sale size is modest relative to total holdings and market cap; no broader implications.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to CYTK shareholders.

Counterpoint

What could challenge this read

Insider sell could be a signal of upcoming negative news.

Key entities

  • Company
    Cytokinetics Inc

    Biotech firm listed on NASDAQ.

  • Executive
    Robert Blum

    President & CEO of Cytokinetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min